ChineseInvestors.com, Inc. (CIIX) Aims to Become One-Stop-Shop for Chinese MMJ Patients
- First online Chinese language cannabidiol (CBD) health products store
- Yelp-style mobile app for locating dispensaries and discussing cannabis products in the U.S.
- Investor consultancy and financial news service
It appears that since antiquity, the Chinese have been aware of the therapeutic effect of cannabinoids. References in a manuscript with the authoritative title ‘Additional Records of Famous Physicians’, dating from the sixth century AD, point to their use as analgesics for “relieving impediment,” essentially the relief of pain. In a country with such a rich tradition of herbal remedies, cannabinoids have played an important role. Now, generations later, ChineseInvestors.com, Inc. (OTCQB: CIIX) continues the tradition of ‘Famous Physicians’ by expanding access to the medicinal benefits of cannabidiol (CBD), a non-psychotropic cannabinoid derived from hemp. The company operates the first online Chinese language CBD health product store. Now, two billion Chinese can order their medicine online and have it delivered to their homes.
The CBD CIIX plans to offer its customers will be extracted from hemp, which means the products will be entirely legal. Hemp, of course, is a variety of the cannabis sativa plant, but, unlike its sister strain marijuana, it has hardly any THC, the psychoactive substance that gives users a ‘high’. Cognizant of this distinction, the Chinese prohibit any involvement in marijuana and enforce that prohibition with harsh penalties, all while allowing the cultivation and production of hemp. In the U.S., however, generally all cannabis cultivation, production and use is illegal under federal law.
CIIX has already dipped its toes in the cannabis waters with its investment in Medicine Man Technologies, Inc. (OTCQB: MDCL). According to SEC filings, CIIX generated $2.3 million in proceeds from a partial exit of its Medicine Man venture in 2016. Medicine Man Technologies provides consulting services related to cultivation, production, and dispensary operations to clients in 11 U.S. states and Puerto Rico.
In February, CIIX launched what it has described as the first CBD health products online store in the Chinese language. The web site, CBD BIO TECH (http://nnw.fm/lrp7R), is intended to be a retail destination for nutritional supplements containing CBD targeting the Asian market through both online and in-store purchases. The announcement follows CIIX’s plan (http://nnw.fm/l11qS) to launch a Chinese language Yelp-style mobile app for locating dispensaries and discussing cannabis products in the U.S., as well as a December announcement (http://nnw.fm/J7Jvm) that it had entered into an alliance with Chinese private equity firm Shenzhen Yuanrong PE Capital to seek out opportunities in medical and recreational cannabis.
Still, there’s more to CIIX than CBD, as the company also operates a consultancy and a financial news service. Services include a variety of information products, web-based tools for investor education, and real-time market commentary, analysis and education in Chinese language character sets.
CIIX was founded in 1999 by Warren Wang, who was born in Shanghai, China. Wang came to the U.S. and later studied finance at St. John’s University in New York. He has served as chief executive officer, chairman of the board, and director of ChineseInvestors.com, Inc. since its inception, with the exception of March 2002 through August 2003, when James S. Toreson served as the company’s chief executive officer as a condition of the Hollingsworth LLC investment.
Wang was previously the vice president of investments for Tradeway Securities Group, a senior financial consultant for Waldron & Co., and a senior account executive at Donald & Co. Securities. He has over 15 years of experience in the financial markets industry and has extensive experience in management, project development, sales, marketing, accounting, and administration. He is a Chartered Financial Analyst (CFA) Candidate, as well as a member of the Market Technicians Association (MTA).
In a recent update, SeeThruEquity increased the price target on CIIX stock to $3.75 to reflect the company’s foray into the cannabis space. The stock is currently quoted at $0.84.
For more information, visit the company’s website at www.ChineseInvestors.com
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
- First online Chinese language cannabidiol (CBD) health products store
- Yelp-style mobile app for locating dispensaries and discussing cannabis products in the U.S.
- Investor consultancy and financial news service
It appears that since antiquity, the Chinese have been aware of the therapeutic effect of cannabinoids. References in a manuscript with the authoritative title ‘Additional Records of Famous Physicians’, dating from the sixth century AD, point to their use as analgesics for “relieving impediment,” essentially the relief of pain. In a country with such a rich tradition of herbal remedies, cannabinoids have played an important role. Now, generations later, ChineseInvestors.com, Inc. (OTCQB: CIIX) continues the tradition of ‘Famous Physicians’ by expanding access to the medicinal benefits of cannabidiol (CBD), a non-psychotropic cannabinoid derived from hemp. The company operates the first online Chinese language CBD health product store. Now, two billion Chinese can order their medicine online and have it delivered to their homes.
The CBD CIIX plans to offer its customers will be extracted from hemp, which means the products will be entirely legal. Hemp, of course, is a variety of the cannabis sativa plant, but, unlike its sister strain marijuana, it has hardly any THC, the psychoactive substance that gives users a ‘high’. Cognizant of this distinction, the Chinese prohibit any involvement in marijuana and enforce that prohibition with harsh penalties, all while allowing the cultivation and production of hemp. In the U.S., however, generally all cannabis cultivation, production and use is illegal under federal law.
CIIX has already dipped its toes in the cannabis waters with its investment in Medicine Man Technologies, Inc. (OTCQB: MDCL). According to SEC filings, CIIX generated $2.3 million in proceeds from a partial exit of its Medicine Man venture in 2016. Medicine Man Technologies provides consulting services related to cultivation, production, and dispensary operations to clients in 11 U.S. states and Puerto Rico.
In February, CIIX launched what it has described as the first CBD health products online store in the Chinese language. The web site, CBD BIO TECH (http://nnw.fm/lrp7R), is intended to be a retail destination for nutritional supplements containing CBD targeting the Asian market through both online and in-store purchases. The announcement follows CIIX’s plan (http://nnw.fm/l11qS) to launch a Chinese language Yelp-style mobile app for locating dispensaries and discussing cannabis products in the U.S., as well as a December announcement (http://nnw.fm/J7Jvm) that it had entered into an alliance with Chinese private equity firm Shenzhen Yuanrong PE Capital to seek out opportunities in medical and recreational cannabis.
Still, there’s more to CIIX than CBD, as the company also operates a consultancy and a financial news service. Services include a variety of information products, web-based tools for investor education, and real-time market commentary, analysis and education in Chinese language character sets.
CIIX was founded in 1999 by Warren Wang, who was born in Shanghai, China. Wang came to the U.S. and later studied finance at St. John’s University in New York. He has served as chief executive officer, chairman of the board, and director of ChineseInvestors.com, Inc. since its inception, with the exception of March 2002 through August 2003, when James S. Toreson served as the company’s chief executive officer as a condition of the Hollingsworth LLC investment.
Wang was previously the vice president of investments for Tradeway Securities Group, a senior financial consultant for Waldron & Co., and a senior account executive at Donald & Co. Securities. He has over 15 years of experience in the financial markets industry and has extensive experience in management, project development, sales, marketing, accounting, and administration. He is a Chartered Financial Analyst (CFA) Candidate, as well as a member of the Market Technicians Association (MTA).
In a recent update, SeeThruEquity increased the price target on CIIX stock to $3.75 to reflect the company’s foray into the cannabis space. The stock is currently quoted at $0.84.
For more information, visit the company’s website at www.ChineseInvestors.com
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
